Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.

GRI Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LA JOLLA, CA, DEC. 12, 2025 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T (NKT) CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF AN AGGREGATE OF 10,666,667 SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF), SERIES F WARRANTS TO PURCHASE UP TO 10,666,667 SHARES OF COMMON STOCK (THE "SERIES F WARRANTS"), AT A COMBINED PUBLIC OFFERING PRICE OF $0.75 PER SHARE (OR PER COMMON STOCK EQUIVALENT IN LIEU THEREOF) AND ACCOMPANYING SERIES F WARRANT. THE SERIES F WARRANTS HAVE AN EXERCISE PRICE OF $0.75 PER SHARE AND ARE EXERCISABLE IMMEDIATELY UPON ISSUANCE AND WILL EXPIRE ON THE FIFTH ANNIVERSARY OF THE INITIAL ISSUANCE DATE.

GRI BIO ANNOUNCES CLOSING OF $8.0 MILLION PUBLIC OFFERING

LA JOLLA, CA, DEC. 11, 2025 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T (NKT) CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE PRICING OF A BEST EFFORTS PUBLIC OFFERING OF AN AGGREGATE OF 10,666,667 SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) AND SERIES F WARRANTS TO PURCHASE UP TO 10,666,667 SHARES OF COMMON STOCK (THE SERIES F WARRANTS), AT A COMBINED PUBLIC OFFERING PRICE OF $0.75 PER SHARE (OR PER COMMON STOCK EQUIVALENT IN LIEU THEREOF) AND ACCOMPANYING SERIES F WARRANT. THE SERIES F WARRANTS WILL HAVE AN EXERCISE PRICE OF $0.75 PER SHARE AND WILL BE EXERCISABLE IMMEDIATELY UPON ISSUANCE. THE SERIES F WARRANTS WILL EXPIRE ON THE FIVE-YEAR ANNIVERSARY OF THE INITIAL ISSUANCE DATE. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT DECEMBER 12, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

GRI BIO ANNOUNCES PRICING OF $8,000,000 MILLION PUBLIC OFFERING

STUDY MET ITS PRIMARY ENDPOINT DEMONSTRATING THAT GRI-0621 WAS WELL TOLERATED OVER 12 WEEKS OF TREATMENT, WITH NO DRUG-RELATED SEVERE OR SERIOUS ADVERSE EVENTS AND NO INCREASE IN GI ISSUES WHEN USED WITH EXISTING APPROVED TREATMENTS

GRI BIO ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)

NO DECLINE IN LUNG FUNCTION OBSERVED AT 6-WEEK INTERIM ANALYSIS BUILDS UPON POSITIVE SAFETY AND BIOMARKER DATA

GRI BIO REPORTS 6-WEEK INTERIM LUNG FUNCTION DATA IN ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)

LIVE VIDEO WEBCAST ON WEDNESDAY, AUGUST 20 TH AT 2:20 PM ET LA JOLLA, CA, AUG. 14, 2025 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T (NKT) CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, THAT IT WILL PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH BEING HELD VIRTUALLY AUGUST 19-21, 2025. DETAILS FOR THE PRESENTATION ARE AS FOLLOWS: DATE AND TIME: WEDNESDAY, AUGUST 20, 2025 AT 2:20 PM ET PRESENTER: MARC HERTZ, PHD, PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR REGISTRATION LINK: HERE ABOUT WEBULL FINANCIAL WEBULL FINANCIAL IS A LEADING ONLINE BROKERAGE PLATFORM COMMITTED TO EMPOWERING SELF-DIRECTED INVESTORS WITH INNOVATIVE TOOLS AND CUTTING-EDGE TECHNOLOGY.

GRI BIO TO PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH

GRI BIO CEO, MARC HERTZ, PARTICIPATES IN VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT

LONDON, JULY 31, 2025 (GLOBE NEWSWIRE) -- DIGINEX LIMITED (DIGINEX OR THE COMPANY) (NASDAQ: DGNX), A LEADING PROVIDER OF SUSTAINABILITY REGTECH SOLUTIONS, IS DELIGHTED TO ANNOUNCE THE APPOINTMENTS OF ANDREW HARLING AS CHIEF COMMERCIAL OFFICER AND MATTHEW RUSK AS VICE PRESIDENT OF STRATEGIC RELATIONSHIPS, AMERICAS, EFFECTIVE IMMEDIATELY. THESE KEY ADDITIONS TO THE SENIOR TEAM REINFORCE DIGINEX'S COMMITMENT TO ACCELERATING GROWTH AND ADVANCING INNOVATION IN SUSTAINABILITY WORLDWIDE.

TWO SENIOR EXECUTIVES FROM S&P AND THE GLOBAL REPORTING INITIATIVE (GRI) JOIN THE DIGINEX TEAM

 VIDEO WEBCAST NOW AVAILABLE ON-DEMAND LA JOLLA, CA, JULY 22, 2025 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T (NKT) CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED MARC HERTZ, PHD, PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR OF GRI BIO, PARTICIPATED IN THE VIRTUAL INVESTOR WHAT'S YOUR STORY SUMMER SPOTLIGHT ON-DEMAND CONFERENCE. AS PART OF THE EVENT, DR. HERTZ DOVE DEEPER INTO HIS DEDICATION TO THE COMPANY, HOW HE GOT TO WHERE HE IS TODAY AND PROVIDED INSIGHT INTO WHY HE IS SO PASSIONATE ABOUT THE COMPANY'S PROGRAMS IN DEVELOPMENT.

GRI BIO PARTICIPATES IN THE VIRTUAL INVESTOR WHAT'S YOUR STORY SUMMER SPOTLIGHT ON-DEMAND CONFERENCE

CURRENTLY AVAILABLE TREATMENTS FOR IPF ARE LIMITED TO ONLY TWO APPROVED DRUGS THAT COME WITH SIGNIFICANT SIDE-EFFECTS, LIMITED PATIENT COMPLIANCE AND NO IMPACT ON SURVIVAL

GRI BIO COMPLETES ENROLLMENT IN PHASE 2A STUDY OF GRI-0621 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) HAS RECOMMENDED TO CONTINUE THE STUDY AS PLANNED AS THERE ARE NO SAFETY CONCERNS DEMONSTRATED IN THE DATA REVIEWED

GRI BIO'S GRI-0621 DEMONSTRATES ENCOURAGING SAFETY RESULTS AT PLANNED INTERIM 6-WEEK ANALYSIS IN ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)

GRI Bio, Inc.

GRI

Price

Financial Reports

No items found.

Press Releases

GRI Bio, Inc.

GRI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GRI